You’re cruising through a renal pharm block and hit a question that looks like it’s just about “which diuretic does X,” but it’s really testing whether you understand where drugs act, what happens to tubular osmolality, and how that translates into electrolytes, urine findings, and adverse effects. Osmotic diuretics are classic Step bait because they intersect with ICP/IOP, volume status, and a bunch of distractors that sound plausible.
Tag: Renal > Renal Pharmacology & Stones
The Clinical Vignette (Q-bank style)
A 58-year-old man is brought to the ED after a motor vehicle collision. CT shows diffuse cerebral edema with rising intracranial pressure. He is given an IV medication that is freely filtered at the glomerulus and not reabsorbed. Shortly afterward, his urine output increases significantly. Which of the following changes is most likely?
A. Decreased NaCl reabsorption in the thick ascending limb
B. Increased urine osmolality and decreased urine volume
C. Increased plasma osmolality with movement of water from brain tissue into the intravascular space
D. Decreased K secretion in the collecting duct due to blockade of ENaC
E. Decreased Ca excretion
Correct answer: C
Why the Correct Answer Is C (Osmotic diuretic: mannitol)
What mannitol does (mechanism)
Mannitol is an osmotic diuretic:
- Freely filtered at the glomerulus
- Not reabsorbed (stays in the tubular lumen)
- Raises tubular fluid osmolality → holds water in the lumen → increases urine volume
- Also raises plasma osmolality (especially early after infusion) → pulls water out of cells into plasma
Why it helps in this vignette (clinical use)
In cerebral edema / elevated ICP, mannitol:
- Increases plasma osmolality
- Creates an osmotic gradient that draws water:
- from brain tissue → intravascular space
- Then the kidney excretes the excess water (diuresis)
So the best described physiologic change is:
Increased plasma osmolality with movement of water from brain tissue into the intravascular space.
High-yield adverse effect pattern
The dangerous twist: mannitol can cause pulmonary edema / heart failure exacerbation because it:
- Expands intravascular volume first (water shifts into plasma)
- Then causes diuresis later
So avoid / use extreme caution in:
- CHF
- Pulmonary edema
- Severe anuria (won’t be filtered, won’t work)
Key Physiology Snapshot (Step-friendly)
Where does mannitol act?
Primarily in:
- Proximal tubule
- Thin descending limb of Henle
These segments are water-permeable, so increasing luminal osmolality strongly reduces water reabsorption.
What happens to urine?
- Urine volume: increases
- Urine osmolality: often decreases overall (lots of water is retained in lumen), though it can be nuanced depending on timing and med delivery—on exams, the key is water diuresis and increased urinary loss of water.
What happens to electrolytes?
Because water stays in the tubule, you also get increased excretion of:
- Na
- K
- Ca
- Mg
- Phosphate
Not because mannitol blocks a transporter—because flow and solvent drag increase excretion.
Systematically Crushing the Distractors
A. Decreased NaCl reabsorption in the thick ascending limb
This describes loop diuretics (furosemide, bumetanide, torsemide, ethacrynic acid).
Loop diuretics inhibit:
- Na-K-2Cl (NKCC2) in the thick ascending limb
High-yield consequences:
- ↑ Na delivery distally → ↑ K and H secretion → hypokalemic metabolic alkalosis
- ↓ medullary hypertonicity → less urine concentrating ability
- ↑ Ca excretion (loops “lose Ca”)
Why it’s wrong here:
- The stem explicitly describes a drug that is filtered and not reabsorbed (osmotic agent), and the clinical scenario is classic mannitol for ICP.
B. Increased urine osmolality and decreased urine volume
This is the opposite of what a diuretic should do.
Patterns to remember:
- Diuretics increase urine volume.
- ADH (or dehydration) is what decreases urine volume and increases urine osmolality.
Why it’s wrong:
- Mannitol increases urine output; it does not concentrate urine the way ADH does.
D. Decreased K secretion in the collecting duct due to blockade of ENaC
This describes amiloride or triamterene (K-sparing diuretics).
ENaC blockers:
- Act in the collecting duct (principal cells)
- ↓ Na reabsorption → ↓ lumen-negative potential → ↓ K secretion
- Major adverse effect: hyperkalemia
Classic association (Step 1/2):
- Liddle syndrome treatment: amiloride/triamterene
- Lithium-induced nephrogenic DI: amiloride helps by blocking lithium entry via ENaC
Why it’s wrong:
- The stem’s drug is an osmotic agent used for ICP, not an ENaC blocker.
E. Decreased Ca excretion
This describes thiazide diuretics (HCTZ, chlorthalidone, indapamide).
Thiazides inhibit:
- Na/Cl cotransporter (NCC) in the distal convoluted tubule
High-yield consequences:
- ↓ Ca excretion (increased Ca reabsorption)
- “Thiazides save Ca”
Why it’s wrong:
- Osmotic diuretics tend to increase urinary losses broadly (water + electrolytes). Decreased Ca excretion is a thiazide signature.
Quick Comparison Table (Know this cold)
| Class | Example | Site | Primary Target | Urine Ca | Acid/Base | Signature Uses / Notes |
|---|---|---|---|---|---|---|
| Osmotic | Mannitol | PCT, thin descending limb | ↑ Tubular osmolality | ↑ (tends to increase excretion) | Variable | ↓ ICP/IOP; can cause pulmonary edema (volume expansion) |
| Loop | Furosemide | Thick ascending limb | NKCC2 inhibition | ↑ | Metabolic alkalosis | Edema, HF, hypercalcemia treatment |
| Thiazide | HCTZ | DCT | NCC inhibition | ↓ | Metabolic alkalosis | HTN; prevents Ca stones (↓ urine Ca) |
| K-sparing (ENaC block) | Amiloride | Collecting duct | ENaC inhibition | Minimal | Acidosis risk | HyperK; Liddle; lithium nephrogenic DI |
| K-sparing (aldo antag.) | Spironolactone | Collecting duct | Aldo receptor block | Minimal | Acidosis risk | HyperK; HF mortality benefit; antiandrogen effects |
Stones Tie-In: Where Osmotic Diuretics Fit (and Where They Don’t)
When questions mix “renal pharm & stones,” they often want you to remember:
Thiazides are stone-relevant (big time)
- Decrease urinary Ca → used to prevent calcium oxalate/phosphate stones in hypercalciuria.
Mannitol is not a stone-prevention drug
- Mannitol is mainly for:
- Increased ICP
- Increased intraocular pressure (acute glaucoma)
- It may increase excretion of electrolytes and water, but it’s not the standard approach to recurrent calcium stones.
High-yield stone prevention adjuncts (rapid recall):
- Calcium oxalate stones: thiazides, citrate; normal dietary calcium, low oxalate, hydration
- Uric acid stones: alkalinize urine (potassium citrate), allopurinol if needed
- Cystine stones: hydration, alkalinization, tiopronin/penicillamine
Exam-Day “If You See Mannitol…” Checklist
Look for:
- IV therapy
- Brain swelling / head trauma / ICP or acute glaucoma
- A description like “filtered and not reabsorbed”
- Then pick effects consistent with:
- ↑ plasma osmolality → water shifts into intravascular space
- ↑ urine output
- Risk of pulmonary edema / CHF exacerbation